β-Cells in Type 2 Diabetes: A Loss of Function and Mass
- 1 October 2004
- journal article
- review article
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 62 (Suppl. 3) , 67-73
- https://doi.org/10.1159/000080503
Abstract
Type 2 diabetes mellitus manifests itself in individuals who lose the ability to produce sufficient amounts of insulin to maintain normoglycaemia in the face of insulin resistance. The ability to secrete adequate amounts of insulin depends on β-cell function and mass. Chronic hyperglycaemia is detrimental to pancreatic β-cells, causing impaired insulin secretion and playing an essential role in the regulation of β-cell turnover. This paper will address the effect of chronically elevated glucose levels on β-cell turnover and function. In previous studies we have shown that elevated glucose concentrations induce apoptosis in human β-cells due to an interaction between constitutively expressed Fas ligand and upregulated Fas. Human β-cells produce interleukin (IL)-1β in response to high glucose concentrations, independently of an immune-mediated process. This was antagonized by the IL-1 receptor antagonist (IL-1Ra), a naturally occurring anti-inflammatory cytokine also found in the β-cell. Therefore the balance of IL-1β and IL-1Ra may play a crucial role in the pathogenesis of diabetes. Inhibition of glucotoxicity represents a promising therapeutic stratagem in diabetes therapy to preserve functional β-cell mass.Keywords
This publication has 19 references indexed in Scilit:
- Apoptosis and occurrence of Bcl-2, Bak, Bax, Fas and FasL in the developing and adult rat endocrine pancreasBrain Structure and Function, 2000
- Insulin Resistance Is Not Necessarily an Essential Component of Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2000
- Sustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F CellsBiochemical and Biophysical Research Communications, 2000
- Apoptosis by Death FactorCell, 1997
- Stroke Incidence, Case Fatality, and Mortality in the WHO MONICA ProjectStroke, 1995
- Interleukin-1 Receptor Antagonist Prevents Low-Dose Streptozotocin-Induced Diabetes in MiceBiochemical and Biophysical Research Communications, 1994
- Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic β-cell destruction in insulin-dependent diabetes mellitusCytokine, 1993
- An interleukin-1 receptor antagonist protein protects insulin-producing Beta cells against suppressive effects of interleukin-1?Diabetologia, 1991
- Glucagon physiology and pathophysiology in the light of new advancesDiabetologia, 1985
- The pancreatic islets in diabetesThe American Journal of Medicine, 1981